Type 2 Diabetes Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults who volunteer to participate and are able to give written consent
- People who have been diagnosed with Type 2 diabetes and have a blood sugar control reading (HbA1c) below 10%
- People who have peripheral arterial disease (reduced blood flow to the legs) that has progressed to a serious stage (Fontaine Stage IV), meaning a foot ulcer is present
- People whose foot ulcer does not require emergency surgery, classified as Wagner Stage 1 or above (confirm with trial site)
- People aged 18 years or older
Who may not be able to join:
- People experiencing sudden, severe loss of blood flow to the leg (acute leg ischemia), with symptoms such as sudden pain, pale skin, numbness, loss of pulse, or shock
- People diagnosed with Type 1 diabetes (confirmed by specific antibody tests)
- People under 18 years of age, or those unable to give informed consent
- Women who are pregnant or breastfeeding
- People currently receiving or who have recently received certain medications, including immunosuppressive drugs, immunomodulators, chemotherapy, or antibiotic therapy within 2 weeks before the trial starts
- People with diseases affecting the pancreas
- People with severe neurological or psychiatric conditions
- People who have had a diagnosis of cancer within the past 5 years
- People who have taken part in another interventional clinical trial or received an experimental medication within the last 30 days
- People who have donated blood or plasma within the last 3 months
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Malte Kelm, Prof., Clinic for Cardiology, Pneumology and Angiology at University Hospital Düsseldorf
Phone: +49 (0)211 81 08753
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Effect of PTA within 48h on changes of the wound area
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.